MOSAIC

Regimen

Experimental
FOLFOX4 (5-FU/LV + oxaliplatin 85 mg/m² Q2W × 12 cycles)
Control
FL (fluorouracil + leucovorin) × 12 cycles alone

Population

Stage II or III colon cancer after curative resection (N=2,246), adjuvant FOLFOX4 vs 5-FU/LV.

Key finding

3-year DFS: FOLFOX4 78.2% vs FL 72.9% (HR 0.77, P=0.002); Stage III benefit confirmed; grade 3 sensory neuropathy 12.4% during treatment, declining to 1.1% at 1 year; paradigm-defining trial establishing FOLFOX as adjuvant standard.

Source: PMID 15175436

Timeline

    Guideline citations

    • NCCN Colon (p.93)